BofA analyst Joanna Gajuk moved to No Rating on Select Medical (SEM) after the company received a non-binding indication of interest from Executive Chairman and co-founder Robert Ortenzio to acquire all of the outstanding shares for $16.00 to $16.20 per share in cash. The firm is “not surprised” by the offer given that the stock has been trading at a depressed valuation, but views shares as no longer trading on fundamentals given the offer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEM:
- Select Medical Receives Acquisition Proposal from Co-Founder
- Select Medical acknowledges Executive Chairman’s take-private proposal
- Select Medical’s Earnings Call Highlights Growth Amid Challenges
- Select Medical price target lowered to $17 from $18 at Mizuho
- Select Medical Reports Strong Q3 2025 Financial Results